Characteristics of Analgesic Patch Formulations.
Identifieur interne : 000034 ( Main/Corpus ); précédent : 000033; suivant : 000035Characteristics of Analgesic Patch Formulations.
Auteurs : Srinivas Nalamachu ; Jeffrey GudinSource :
- Journal of pain research [ 1178-7090 ] ; 2020.
Abstract
Topical and transdermal formulations are a common means of pharmaceutical drug delivery. If a drug is able to penetrate transcutaneously, the skin is an ideal site for the delivery of medications for both local (topical) and systemic (transdermal) effects. The administration of analgesics through the skin poses several potential advantages to those administered orally including compliance, the ability to deliver a drug to a peripheral target site and more stable and sustained plasma levels. One method of drug delivery is with the use of patch formulations - also known as patch systems. Typically, transdermal patches deliver medications intended to reach the systemic circulation, whereas topical patches are designed to keep medication localized for targeted delivery in proximity to the application site. There are a variety of technologies and materials utilized in patches, as well as penetration and formulation enhancers that ultimately affect the performance, efficacy and safety of the patch system. The degree of adherence to the skin is also of critical importance in drug delivery. Patches that lift up or fall off before the prescribed time period may represent a therapeutic failure and must be replaced, increasing patch utilization and cost to the healthcare system or to the patient. The added risk from accidental exposure makes poor patch adhesion a safety issue as well. A variety of analgesics are currently available as patch formulations including local anesthetics, capsaicin, nonsteroidal anti-inflammatory drugs and opioids. This review will highlight each of those patch delivery systems and introduce newer patch technologies that lend towards improved adhesion and compliance. Understanding the designs, limitations and benefits of patch systems will allow clinicians to select between these therapies when appropriate for their patients.
DOI: 10.2147/JPR.S270169
PubMed: 33061549
PubMed Central: PMC7520099
Links to Exploration step
pubmed:33061549Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characteristics of Analgesic Patch Formulations.</title><author><name sortKey="Nalamachu, Srinivas" sort="Nalamachu, Srinivas" uniqKey="Nalamachu S" first="Srinivas" last="Nalamachu">Srinivas Nalamachu</name><affiliation><nlm:affiliation>Mid America PolyClinic, Overland Park, KS, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Kansas City University of Medicine and Biosciences, Kansas City, MO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gudin, Jeffrey" sort="Gudin, Jeffrey" uniqKey="Gudin J" first="Jeffrey" last="Gudin">Jeffrey Gudin</name><affiliation><nlm:affiliation>Department of Anesthesiology and Pain Management, Englewood Hospital and Medical Center, Englewood, NJ, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Anesthesiology and Perioperative Medicine, Rutgers New Jersey School of Medicine, Newark, NJ, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33061549</idno><idno type="pmid">33061549</idno><idno type="doi">10.2147/JPR.S270169</idno><idno type="pmc">PMC7520099</idno><idno type="wicri:Area/Main/Corpus">000034</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000034</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Characteristics of Analgesic Patch Formulations.</title><author><name sortKey="Nalamachu, Srinivas" sort="Nalamachu, Srinivas" uniqKey="Nalamachu S" first="Srinivas" last="Nalamachu">Srinivas Nalamachu</name><affiliation><nlm:affiliation>Mid America PolyClinic, Overland Park, KS, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Kansas City University of Medicine and Biosciences, Kansas City, MO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gudin, Jeffrey" sort="Gudin, Jeffrey" uniqKey="Gudin J" first="Jeffrey" last="Gudin">Jeffrey Gudin</name><affiliation><nlm:affiliation>Department of Anesthesiology and Pain Management, Englewood Hospital and Medical Center, Englewood, NJ, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Anesthesiology and Perioperative Medicine, Rutgers New Jersey School of Medicine, Newark, NJ, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of pain research</title><idno type="ISSN">1178-7090</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Topical and transdermal formulations are a common means of pharmaceutical drug delivery. If a drug is able to penetrate transcutaneously, the skin is an ideal site for the delivery of medications for both local (topical) and systemic (transdermal) effects. The administration of analgesics through the skin poses several potential advantages to those administered orally including compliance, the ability to deliver a drug to a peripheral target site and more stable and sustained plasma levels. One method of drug delivery is with the use of patch formulations - also known as patch systems. Typically, transdermal patches deliver medications intended to reach the systemic circulation, whereas topical patches are designed to keep medication localized for targeted delivery in proximity to the application site. There are a variety of technologies and materials utilized in patches, as well as penetration and formulation enhancers that ultimately affect the performance, efficacy and safety of the patch system. The degree of adherence to the skin is also of critical importance in drug delivery. Patches that lift up or fall off before the prescribed time period may represent a therapeutic failure and must be replaced, increasing patch utilization and cost to the healthcare system or to the patient. The added risk from accidental exposure makes poor patch adhesion a safety issue as well. A variety of analgesics are currently available as patch formulations including local anesthetics, capsaicin, nonsteroidal anti-inflammatory drugs and opioids. This review will highlight each of those patch delivery systems and introduce newer patch technologies that lend towards improved adhesion and compliance. Understanding the designs, limitations and benefits of patch systems will allow clinicians to select between these therapies when appropriate for their patients.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33061549</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7090</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Journal of pain research</Title><ISOAbbreviation>J Pain Res</ISOAbbreviation></Journal><ArticleTitle>Characteristics of Analgesic Patch Formulations.</ArticleTitle><Pagination><MedlinePgn>2343-2354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/JPR.S270169</ELocationID><Abstract><AbstractText>Topical and transdermal formulations are a common means of pharmaceutical drug delivery. If a drug is able to penetrate transcutaneously, the skin is an ideal site for the delivery of medications for both local (topical) and systemic (transdermal) effects. The administration of analgesics through the skin poses several potential advantages to those administered orally including compliance, the ability to deliver a drug to a peripheral target site and more stable and sustained plasma levels. One method of drug delivery is with the use of patch formulations - also known as patch systems. Typically, transdermal patches deliver medications intended to reach the systemic circulation, whereas topical patches are designed to keep medication localized for targeted delivery in proximity to the application site. There are a variety of technologies and materials utilized in patches, as well as penetration and formulation enhancers that ultimately affect the performance, efficacy and safety of the patch system. The degree of adherence to the skin is also of critical importance in drug delivery. Patches that lift up or fall off before the prescribed time period may represent a therapeutic failure and must be replaced, increasing patch utilization and cost to the healthcare system or to the patient. The added risk from accidental exposure makes poor patch adhesion a safety issue as well. A variety of analgesics are currently available as patch formulations including local anesthetics, capsaicin, nonsteroidal anti-inflammatory drugs and opioids. This review will highlight each of those patch delivery systems and introduce newer patch technologies that lend towards improved adhesion and compliance. Understanding the designs, limitations and benefits of patch systems will allow clinicians to select between these therapies when appropriate for their patients.</AbstractText><CopyrightInformation>© 2020 Nalamachu and Gudin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nalamachu</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mid America PolyClinic, Overland Park, KS, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kansas City University of Medicine and Biosciences, Kansas City, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudin</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Management, Englewood Hospital and Medical Center, Englewood, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Rutgers New Jersey School of Medicine, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>J Pain Res</MedlineTA><NlmUniqueID>101540514</NlmUniqueID><ISSNLinking>1178-7090</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">capsaicin</Keyword><Keyword MajorTopicYN="N">lidocaine</Keyword><Keyword MajorTopicYN="N">patch adhesion</Keyword><Keyword MajorTopicYN="N">topical</Keyword><Keyword MajorTopicYN="N">transdermal</Keyword></KeywordList><CoiStatement>Dr Nalamachu has received honorarium/grants from or has consulted with Scilex, Collegium, Pfizer and Lilly in the past 1 year; reports personal fees/grants from DSI, Collegium, Purdue, Neurana, and Astra Zeneca, is a speaker for Salix, outside the submitted work. Dr Gudin reports consulting or advisory fees from Averitas Pharma, BDSI, Glaxo, Hisamitsu, Lily, Pfizer, Salix, Sanofi, Scilex, US Worldmeds, and Versea and stock options for Virpax Pharmaceuticals. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33061549</ArticleId><ArticleId IdType="doi">10.2147/JPR.S270169</ArticleId><ArticleId IdType="pii">270169</ArticleId><ArticleId IdType="pmc">PMC7520099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pain. 1999 Apr;80(3):533-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10342414</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Health Syst Pharm. 2012 Jan 15;69(2):116-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22215357</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2004 Jul;127(Pt 7):1606-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15128618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1995 Feb;37(2):246-53</Citation><ArticleIdList><ArticleId IdType="pubmed">7847866</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2006 Aug;64(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16797171</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 1996 Apr;65(1):39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8826488</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Res. 2016 Nov 09;9:993-999</Citation><ArticleIdList><ArticleId IdType="pubmed">27877065</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2020 Jan;132(1):28-36</Citation><ArticleIdList><ArticleId IdType="pubmed">31900074</ArticleId></ArticleIdList></Reference><Reference><Citation>Skin Res Technol. 2008 Aug;14(3):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19159369</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Sci. 2013 Dec 18;50(5):623-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23680534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Neurol Disord. 2013 Sep;6(5):287-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23997814</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2012 Jun;28(6):937-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22551228</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Des Devel Ther. 2018 Dec 13;12:4231-4240</Citation><ArticleIdList><ArticleId IdType="pubmed">30587919</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2011 Oct;107(4):490-502</Citation><ArticleIdList><ArticleId IdType="pubmed">21852280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2007 Jul 1;582(Pt 1):317-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17510181</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2015 May;172(9):2179-209</Citation><ArticleIdList><ArticleId IdType="pubmed">25560046</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Pharm Sci. 2017 Nov;12(6):487-497</Citation><ArticleIdList><ArticleId IdType="pubmed">32104362</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 2003 Aug;121(2):231-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12880413</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 2013 Sep;154(9):1632-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23707278</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Deliv. 2012 Jan;9(1):33-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22171789</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Sports Med. 2018 May;52(10):642-650</Citation><ArticleIdList><ArticleId IdType="pubmed">29436380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain. 2017 Jan;18(1):42-53</Citation><ArticleIdList><ArticleId IdType="pubmed">27746370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000034 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000034 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33061549
|texte= Characteristics of Analgesic Patch Formulations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33061549" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |